MicroRNAs (miRNAs), which are small single-stranded RNA molecules composed of 18-23 nucleotides, act as oncogenes or tumor suppressor genes playing important roles in tumor formation, infiltration and metastasis. Subsequently, miRNAs expression contributes to cancer diagnosis and prognosis. Gastric cancer currently has high morbidity and mortality among all malignant tumors, yet it lacks early specific diagnostic markers and effective treatments. In gastric cancer, many studies have detected abnormal expression forms of miRNAs and confirmed their involvement in its tumorigenesis, progression, invasion and metastasis. They may become valuable diagnostic markers and therapeutic targets for gastric cancer. Studying the role of miRNAs in gastric cancer and its relationship with diagnostic and prognostic parameters might help to improve the sensitivity of diagnosis as well as the efficacy of gastric cancer treatment. This review aims to highlight the advancements which might provide new methods for early clinical diagnosis and effective therapeutic options, along with predict response to treatment for gastric cancer.
Gastric cancer is the most common gastrointestinal malignant tumor which poses a serious threat to human health. According to statistical data in CA2010, there are 934 000 newly diagnosed cases of gastric cancer patients each year, and two-thirds of them are located in Eastern Europe, South America and Asia. The incidence of gastric cancer in Asian countries is higher than others, furthermore, Chinese account for 42% of Asian patients. 1 The prognosis of gastric cancer depends on the stage when diagnosed, and the later stage carries poor prognosis.
In general, about 50% of these patients have had metastasis at the time of diagnosis. Subsequently, the long-term curative effect is poor. Though great progress has been made in the examination and treatment, it could only improve curative effect of early detection, but not the curative effect in case of middle and late stages. Current treatment still cannot significantly prolong the survival time of gastric cancer patients.
MicroRNAs (miRNAs) are endogenous non-coding small molecule RNAs, a subset of 19-24 ribonucleotide in length. miRNA was firstly discovered in nematode Caenorhabditis elegans, and then a variety of such molecules were found in plants and animals. In living cells, the miRNA molecules are modified by Drosha and Dicer enzyme to induce degradation or silence of target mRNAs after transcription, thus inhibiting protein synthesis. 2 It is predicted that about 30% of the mRNAs in the human body are the miRNA targets, and each miRNA can regulate hundreds of genes. They have a role on the organ development, differentiation and function, as well as tumor formation, progression, invasion and metastasis. Studies on function of miRNA proved that it could be an oncogene or a tumor suppressor gene. The role of miRNA depends on its target genes. MicroRNA targeting oncogenes could act as a tumor suppressor, whereas targeting tumor suppressor genes could be a potential oncogene. At the same time, the expression and function of microRNAs were regulated by various factors, such as gene sequence, phosphorylation level, miRNAs modification enzyme and so on. Many recent studies on miRNA revealed its involvement in pathogenesis of different tumors including gastric carcinoma.
miRNAs AND TUMORIGENESIS OF GASTRIC CANCER
As a post-transcriptional gene regulator, miRNAs are involved in many cellular processes, including the development, differentiation, proliferation, apoptosis and stress reaction and so on. Human malignant tumors including gastric cancer are usually characterized by abnormal expression of a large number of genes. Some of them may lead to tumorgenesis as a consequence. 3 miR-106-25b family including miR-25, miR-106 and miR-93b shows higher expression in primary tumors of stomach and in all of gastric cancer cell lines, which may take part in the process of the occurrence of gastric cancer. 4 In a study on 365 cases of gastric cancer, 15 miRNAs and 24 families of miRNAs were isolated by application of 133 labeled-single nucleotide polymorphisms. The results suggest that miR-25, miR-29, miR-93 and miR-106-b may have an important role in the genetic susceptibility and the molecular mechanisms of gastric cancer. 5 miR-181-c is critical to the occurrence of gastric cancer through regulating oncogenes NOTCH4 and KRAS. 6 When exposed to N-nitrose compound (MNNG (N-methyl-N-nitro-N'-nitrosoguanidine)) in vivo or in vitro, miR-21 is activated during the process of malignant transformation and tumorigenesis, which could induce gastric tumor. After activation, miR-21 expression level is time-and dose-dependent and it may have a role in chemical tumorigenesis through the regulation of death receptor Fas ligand and BTG2 (B-cell translocation gene 2). 7 Genetic variations of miR-25, miR-29, miR-93 and miR-106-b may induce increased genetic susceptibility of gastric cancer, and participate in the molecular mechanisms of gastric tumorigenesis. 5 Disturbance of pro-oxidant-antioxidant balance can enhance the oxidative damage to gastric tissues and then promote the occurrence of cancer. Reactive oxygen species induced by raising miR-21 expression level in gastric cells, which cut the expression of PDCD4 (programmed cell death protein 4), may eventually bring about tumorigenesis. 8 Both the overexpression of miR-21 and low expression of PDCD4 are significantly related to the degree of gastric cancer differentiation, clinical stage, as well as local and distant lymph node metastasis.
The gene polymorphism of G/A in miR-27a suppresses the expression of mature miR-27a, which could reduce the genetic susceptibility to gastric cancer. 9 In addition, in eight kinds of gastric cancer cell lines and human gastric cancer tissues, the obviously downregulated miR-212 suppresses its target gene MeCP2 (methyl-CpG-binding protein) expression which is associated with occurrence of gastric cancer. 10 Tumor-promoting effects of miRNAs The aberrant expressions of miR-17-5p, miR-20a, miR-21, miR-92, miR-106-a and miR-155 are associated with tumorigenicity, and their elevated levels can be detected in many types of cancers. In addition, inhibition of miR-27a's expression can depress the growth of gastric adenocarcinoma, which proved that it could be a gastric oncogene. 11 Some miRNAs can promote the development of gastric cancer through direct or indirect regulation of oncogenes or tumor suppressor genes. Increased expressions of miR-17, miR-18a/b, miR-19a, miR-20a/b, miR-21, miR-106-a/b, miR-340, miR-421 and miR-658 in gastric cancer are related to downregulated levels of tumor suppressor genes Rb and PTEN (phosphatase and tensin homolog). These miRNAs may have a role in accelerating the development of gastric cancer. 12 Furthermore, exceptional expression of miR-19a dramatically facilitates gastric cell proliferation and tumorigenesis in vitro and in vivo by inhibiting tumor suppressor genes SOCS1 (suppressor of cytokine signaling 1). 13 Moreover, the overexpression of miR-21 in gastric cancer is directly correlated with higher degree of differentiation, local invasion and lymph node metastasis. While lowering the expression of miR-21 could significantly restrain these biological behaviors by raising the expression of tumor suppressor gene PTEN in BGC-823 cells. 14 Except for PDCD4 and PTEN, miR-21, as an oncogenic factor, could target many other tumor suppressor genes including TPM1 (tropomyosin 1) and BTG2 (BTG family member 2). 15 miR-25 is obviously overexpressed both in human gastric cancer tissues and in cell lines, as well as plays a pivotal role in the tumorigenesis and metastasis. And it may promote gastric carcinoma cell growth by targeting and regulating RECK (reversion-inducing cysteine-rich protein with Kazal motifs) gene. 16 Suppressing the expression of miR-106b can activate its target gene PTEN and subsequently depress invasion and metastasis of gastric cancer cell, which indicated that miR-106b, as a oncogene, could become a therapeutic target gene. 17, 18 Overexpression of miR-150 in gastric cancer tissues and various gastric cancer cell lines promotes tumorigenesis and cell proliferation through negative regulation of tumor suppressor gene EGR2 (early growth response 2). 19 miR-181a can promote proliferation, aggregation, invasion and migration of gastric cancer cells SGC-7901, as well as restrain apoptosis by direct inhibition of tumor suppressor KLF6. 20 miR-223 acts as a proto-oncogene through post-transcription regulation of its target gene FBXW7/hCdc4 (a cancer suppressor gene regulating apoptosis, proliferation and invasion of gastric cancer cells). 21 miR-301a can directly suppress RUNX3 (Runtrelated transcription factor 3) expression and accordingly advance cell growth, migration and invasion. 22 miR-363, via raising the expression of MBP-1 (c-Myc promoter binding protein 1) in gastric cancer SC-M1 cells, causes cell growth, progression, epithelialmesenchymal transformation and tumor formation. Endogenous miR-363 knockout in SC-M1 cells, by downregulating MBP-1, inhibits tumorigenesis and progression. 23 The reduced level of miR-365 in human gastric cancer tissue related to poorly differentiated tumor tissues, infiltration depth and progress stages, and also to the deficiency of PTEN, phosphorylated Akt, p53, cyclin D1 and cdc25A. The PTEN-Akt-p53-miR-365-cyclin D1/cdc25A axis serves as a new mechanism underlying gastric tumorigenesis. 24 miR-372 produces its tumorpromoting effect by downregulating the tumor suppressor gene LATS2 (large tumor suppressor 2), which can regulate gastric cancer cell cycle and apoptosis, and thus contributes to gastric oncogenesis. 25 miR-544 is another cancerogenic miRNA which can promote gastric cancer cell proliferation and cell cycle progression in vitro. Overexpression of miR-544 can inactivate the tumor suppressor gene IRX1 (iroquois homeobox 1) and diminish its expression level in gastric cancer. 26 After combining with the 3ʹ untranslated region of GC-associated CLDN18 (claudin-18 gene) mRNA, the expression of miR-1303 is reduced, which will accordingly promote the occurrence and migration of gastric cancer. In parallel, suppressed miR-1303 can inhibit proliferation, migration and invasion of gastric cancer cells. 27 The gastric tumorigenesis promoting effect for miRNAs may be associated with gene polymorphism. One study on single nucleotide polymorphisms of miR-196a-2 shows that the variant homozygote CC can markedly increase the risk of gastric cancer, which clearly indicates that miR-196a-2 gene mutation may play an important role in the occurrence and progression of gastric cancer. 28 miR-372 also has a key role in the occurrence of gastric cancer by regulating the mRNA level of TNFAIP1 (tumor necrosis factor-alpha-induced protein 1) which controls cell growth. 29 Cell apoptosis and cell cycle regulation are important mechanisms of how miRNAs participate in initiation of gastric cancer. High expression of miR-106a in both gastric cancer tissues and cell lines shows significant negative correlation with the level of Fas gene (cell surface death receptor encoding gene), which thereby weakens Fas-induced apoptosis. 17 The overexpression of miR-125b in gastric cancer HGC-27 cells can distinctly increase cell proliferation and decreases apoptosis. This is a possible mechanism involved in its tumorigenicity. 30 SOX2 (Sex determining region Y-box 2) has positive effect on the growth inhibition by regulating the cell cycle and apoptosis. Both the excessive expression of miR-126 and the decreased expression of SOX2 were found in some gastric cancer cell lines in vitro as well as primary gastric cancer cells, which is found that the phenomenon usually concomitants to gastric tumorigenesis. 31 The expression of miR-146a in gastric cancer tissues was upregulated, moreover, by regulating target genes SMAD family member 4 (SMAD4 (small mothers against decapentaplegic 4)), it could promote cell proliferation and inhibit apoptosis. 32 miR-148a can conduce to gastric cancer cell proliferation by reducing the expression of p27 (kip1), while its knockout can produce the opposite effect. 33 High expression of miR-196a in gastric cancer tissue is directly correlated with tumor size, higher clinical stage and shortened survival time. Futhermore, p27 (kip1)mediated repression in cell proliferation was reverted by exogenous miR-196a expression. 34 Studies were summarized in Table 1 . Abbreviations: miRNA, microRNA; OG, oncogene; TS, tumor suppressor.
Role of MicroRNAs in gastric cancer C Jiang et al
Tumor suppressor effects of miRNAs Let-7 family miRNAs exert tumor-suppression effects through targeting and regulating RAS and HMGA2 oncogenes. 35 miR-9 is another tumor suppressor gene which can inhibit tumor cell growth by adjusting NF-κB (nuclear factor kappa B) expression. 36 in addition, it can suppress RAB34 (member RAS oncogene family) expression and tumor cell migration. 37 On the other hand, opposite results suggest that miR-9 may bind to 3ʹ untranslated region sites of CDX2 to inhibit its expression, and eventually induce gastric cancer cell proliferation. 38 Hypermethylation signals in the upstream region of miR-181C were associated with reduction in its expression. The treatment with 5-mixed nitrogen DNA cytosine nucleoside in gastric cancer cell can increase miR-181C's level and inhibit cell proliferation by modulating NOTCH4 and Kras. 39 Reduced miR-204 expression in gastric cancer could repress RAS activation, cell growth and migration. Downregulation of miR-204 and abnormal activation of RAS participate in the mechanisms of gastric tumorigenesis. 40 miR-212 expression levels in gastric cancer tissues and cell lines (BGC-823, SGC-7901 and MKN-45) are significantly lowered due to excessive hypermethylation of CpG islands. The proto-oncogene Myc is one of target genes of miR-212 and downregulation of miR-212 induced Myc activation has a role in the progress of gastric cancer. 41 In gastric cancer, miR-338-3p is classified as a tumor suppressor gene and the oncogene SSX2IP is one of its target genes. 42 The obviously reduced level of miR-338-3p in gastric cancer is directly related to the aggressiveness of the clinical pathologic features of gastric cancer patients. Restoring the expression of miR-338-3p in gastric cancer SGC-7901 cells can inhibit cell proliferation, migration, invasion and tumorigenicity. miR-375 can block JAK2-STAT3 (signal transducer and activator of transcription 3) signaling pathway and cell proliferation by inhibiting the expression of oncogene JAK2 (Janus kinase 2), and then prevent gastric cancer occurrence as a tumor suppressor gene. 43, 44 It is clear that many miRNAs with tumor suppressor effect work via modulating specific target genes. The tumor suppressive effect of miR-10b should be owed to direct regulation of MAPRE1 (microtubule-associated protein RP/EB family member 1) during gastric oncogenesis. 45 A similar effect produced by miR-24 may be due to inhibition of its target gene RegIV (Regenerating gene type IV). 46 miR-29 may serve as tumor suppressor in gastric tissue by suppressing gene expression of CCND2 and MMP2 (matrix metalloproteinase-2). 47 Similarly, miR-29c can directly target ITGB1. 48 The inhibitory action of miR-34a against gastric tumorigenesis is mediated through the PI3K/Akt pathway by targeting PDGFR (platelet-derived growth factors' receptors) and MET. 49 COX-2 (cyclooxygenase 2) is a key regulatory factor in the occurrence and progression of gastric cancer. miR-101 can inhibit gastric cancer cell proliferation and promote apoptosis in vitro and also has anti-proliferative activity in vivo. These inhibitory effects are tightly related to downregulation of its target gene COX-2. 50 In addition to COX-2, miR-101 can inhibit tumor cell growth, invasion and metastasis by acting on EZH2, Mcl-1 and Fos. 51 Upregulated SPHK1 expression is associated with poor survival in gastric cancer patients. miR-124, by downregulating SPHK1, inhibits gastric cancer cell proliferation. 52 On targeting CCKBR, miR-148b exerts its antineoplastic effect by depressing gastric cancer cell proliferation. 53 miR-200 family members include miR-200a and miR-200b. Their expression was obviously declined after Epstein Barr Virus (EBV) infection in gastric cancer cell lines (MKN74-EBV, MKN7-EBV and NUGC3-EBV), which accordingly resulted in downregulation of E-cadherin protein (which mediates calcium-dependent intercellular adhesion) expression and it is regarded as a key step of EBV-related gastric cancerogenesis. 54 miR-212 can directly target the 3ʹ untranslated region of RBP2 (Retinoblastoma Binding Protein 2) and inhibit its expression, and finally arrest the growth of gastric cancer cells. 55 Low expression of miR-218 in gastric tissues can promote carcinogenesis as a result of excessive activation of the target gene NF-κB, which may be originally a consequence of chronic Helicobacter pylori. 56 miR-219-2-3p, by modulating ERK1/2 related signaling pathways, can inhibit progression and metastasis of gastric cancer. 57 The occurrence of gastric cancer is often characterized by the disorder of transcription factor E2F1 activities. miR-331-3p, by interfering with the activity of E2F1, inhibits cellular growth in vitro and thus could be regarded as a tumor suppressor gene in gastric cancer. Enhancing the expression level of miR-331-3p may be a potential treatment of gastric cancer. 58 miR-370 can directly decrease the expression of protein transcription factor FoxM1 (Forkhead box M1) in gastric cancer cells, so overexpression of miR-370 may depress cell proliferation and gastric oncogenesis. 59 Gene polymorphism and changes in methylation level regulated by miRNAs also have a big role in the process of tumor progression. The G/A polymorphism of miR-27a gene can decrease its expression and reduce the risk of gastric canceration. 9 The overexpression of miR-10b in MGC-803 and HGC-27 cells can significantly induce apoptosis and inhibit cell proliferation, migration and invasion. However, miR-10b was obviously downregulated in gastric cancer tissues due to excessive DNA methylation, which could cause its partial silencing. 60 In 13 gastric cancer cell lines, downregulation of miR-34b/c can be seen as a result of the CpG island methylation of them. Transfection of miR-34b and miR-34c precursor into gastric cancer cells can halt the growth of cells. In gastric cancer tissue samples, miR-34b/c, miR-34b and miR-34c as new tumor-inhibitory molecules were often silenced by DNA methylation. 61 In some gastric cancer cell lines, DNA methylation levels of miR-124a-1/-2/-3 are higher than those of normal gastric cells, at the same time lowering their expression can consequently reduce their inhibitory effect on gastric cancer cell proliferation. 62 The levels of miR-195 and miR-378 were obviously lessened in gastric cancer tissues and cell lines and this was closely related to DNA hypermethylation of their promoter CpG island. Their upregulated expression can significantly restrain the growth of gastric cancer cells and boost the proliferation of normal gastric epithelial cells. 63 Some miRNAs inhibit gastric tumors by modulating cell cycle and apoptosis. Low expression of Let-7a was detected in human gastric cancer tissue and cell lines and its level was directly correlated with the degree of cell differentiation. Overexpressed Let-7a decreases cell proliferation and leads to G1 arrest, which finally depresses the growth of gastric cancer. 64 In the cells with p53 mutation, miR-34 can target Bcl-2, Notch and HMGA2, and enhance chemotherapy sensitivity by cell cycle arrest in G1 phase induced growth inhibition. In addition, it can promote apoptosis by increasing the active form of caspase-3. 65 Downregulated miR-137 expression in gastric cancer tissues correlates with the level of the target gene-encoding Cell Division Cycle 42 (Cdc42). On revival of miR-137 expression, the functional inactivation of Cdc42 can induce gastric cancer cell apoptosis and cell cycle arrest in G1 phase. 66 Downregulation of miR-205 is bound up with the depth of invasion of gastric carcinoma. Inhibiting miR-205 expression significantly promotes the progression of gastric cancer through cell cycle regulation. 67 Results of large-scale microarray assays showed that the expression of miR-218 was obviously downregulated in gastric cancer tissue, while overexpression of miR-218 can inhibit human gastric epithelial AGS cells proliferation and enhance apoptosis. 56 miR-331-3p can prevent G1/S transition in gastric cancer SGC-7901 and AGS cells by interfering with transcriptional factor E2F1 along with repressing gastric cancer cell clone formation and cell growth. 58 miRNA microarray platform covering a total of 470 human miRNAs revealed that the expressions of six miRNAs including miR-375 were significantly lowered in gastric cancer tissues while ectopic expression of miR-375 could remarkably reduce cell vitality by caspase mediated apoptosis, which demonstrated its tumor suppressor function. 68 In gastric cancer BGC-823 cells, miR-429 obviously restrained the proliferation of tumor cells serving as a tumor suppressor. 69 miR-449 also has anti-gastric tumor effect by activating p53, inducing apoptosis and inhibiting cell proliferation. 70 In gastric cancer cell lines (BGC-823 and SNU5), downregulation of miR-663 can cause cell proliferation and tumor formation. 71 In addition, the expression of miR-7 is negatively correlated with interleukin-1β and TNF-α levels in human gastric cancer. In other words, decreased expression of miR-7 is closely related to severe inflammatory response. Downregulation of the tumor suppressor miR-7 induced by inflammation is another new mechanism of gastric tumorigenesis. 72 Significantly reduced miR-126 expression in gastric cancer tissues was relevant to the progress of clinicopathological features, including tumor size, lymph node metastasis, local invasion and tumor-node metastasis stage. 73 Studies were summarized in Table 2 .
miRNAs AND THE INVASION AND METASTASIS OF GASTRIC CANCER
An increasing body of studies showed that miRNAs can control many important tumor-related genes involved in tumor occurrence and progression, and can also regulate the invasion and metastasis of tumor (see Figure 1 ).
miRNAs inhibiting gastric cancer metastasis
Overexpressed Let-7f in gastric cancer tissues can directly target tumor metastasis-related gene MYH9 and inhibit tumor invasion and metastasis. 74 On targeting cancer gene-encoding insulin like growth factor 1 receptor, miR-7 can significantly reverse epithelial-mesenchymal transition process and inhibit metastasis of gastric cancer cells in vivo. 75 The oncogene PDGFR is directly targeted by miR-34a, which suppresses gastric cancer cell proliferation, migration and invasion. 49 miR-101 can not only inhibit multiplication, invasion and migration of gastric cancer cells in vitro but also inhibit their growth in vivo. 51 miR-145 can also attenuate gastric cancer metastasis by inhibiting N-cadherin (CDH2) protein translation, and indirectly by downregulating its downstream effector MMP9. 76 The reduction of miR-148a, a tumor suppressor gene, contributes to gastric cancer metastasis and progression. 77, 78 The overexpression of miR-155 in the gastric cancer SGC-7901 and MKN-45 cell lines can obviously hinder cell migration and adhesion. This function may be associated with reduced expression of its target gene Smad2. 79 The decreased expression of miR-206 could be detected in gastric cancer cell lines and gastric cancer tissues especially in those with lymphatic metastasis or local invasion. Forced expression of miR-206 can inhibit tumorigenesis, proliferation, invasion and metastasis in xenograft vaccinated with gastric cancer SCG-7901 cell. Therefore, miR-206 in gastric cancer acts as a tumor suppressor as well as has a role in regulating tumor cell metastasis. 80 In 80 gastric cancer tissue samples and 4 gastric cancer cell lines, the expression levels of miR-214 were considerably lower than in normal tissues and control cells. There is a remarkably negative correlation between the expression level of miR-214 and gastric cancer lymph node metastasis along with tumor size. Ectopic expression of miR-214 in gastric cancer cell lines SGC-7901 and MKN-45 may weaken tumor migration and invasion abilities. Knockout of miR-214 can largely stimulate the MKN28, BGC-823 and GES-1 cells proliferation, migration and invasion. Colony stimulating factor 1 (CSF-1) is one of the miR-214 target genes and lower expression of miR-214 can prompt gastric cancer cell proliferation, migration and metastasis, which was inversely related to CSF-1 expression. 81 Robo1, the ligand for neural axon guidance factor Slit, is negatively modulated by miR-218. Once the expression of Robo1 is reduced, miR-218 can activate Slit-Robo1 signal pathway and cause gastric cancer cell metastasis. On the contrary, recovering the inhibitory effect on Robo1 in vitro or in vivo, miR-218 can restrain invasion and metastasis of gastric cancer cells. 82 miR-335 can inhibit gastric cancer cell invasion and metastasis via regulation of both Bcl-w and specificity protein 1. Low expression of miR-335 in gastric cancer cells particularly related to aggressiveness of lymph node metastasis, tumor-node metastasis stage and lymphatic vessel invasion. 83 Through direct combination with 3′-translated area of prometastatic gene radixin (RDX), miR-409-3p restrains gastric cancer cell invasion and metastasis. Downregulated miR-409-3p also facilitates lymph node metastasis. 84 Even for the highly metastatic 44As3 cells, miR-516-3p can block their metastasis. 85 Interestingly, the reduced level of miR-574-3p occurred mainly in the early stages of gastric cancer or in cancers with high level of differentiation. miR-574-3p obviously inhibits cell proliferation, invasion and metastasis after transfected into gastric cancer SGC-7901 cells. This is a powerful evidence that miR-574-3p does its work as a tumor suppressor gene in gastric carcinoma. 86 The prominent reduction of miR-625 in gastric cancer tissues and cell lines also shows negative correlation with lymph node metastasis. Studies in vivo and in vitro have demonstrated that miR-625 could obviously inhibit gastric cancer cell invasion and metastasis, which may be owed to direct modification of integrin-linked kinase expression. 87 miRNAs enhancing gastric cancer metastasis Abnormal expression of miR-9 can promote gastric cancer cell proliferation, invasion and metastasis. It often shows lower expression level in gastric cancer tissues than that of normal counterparts. 88 The expression level of miR-10a in the gastric cancer cells is 10 times higher than those of normal gastric mucosa. Compared with early stage, in late stages of gastric cancer, those patients with lymph node metastasis, showed notably raised expression of miR-10a. 89 miR-20a potentiates gastric cancer cells growth, migration and invasion. Moreover, and it can enhance their resistance to chemotherapy (cisplatin and taxol). The role of miR-20a in gastric tumorigenesis is a result of regulating EGR2 signaling pathways. 90 Excessive expression of miR-21 in human gastric cancer tissues and cell lines has been reported. The increased proliferation and invasion were found in human gastric adenocarcinoma AGS cells, while knockout of miR-21 in AGS cells distinctly reduced cell invasion and metastasis abilities. 91 miR-27 also has a pivotal role in regulating gastric cancer metastasis and has potential for clinical treatment. Upregulated miR-27 may encourage metastasis of AGS cells and vice versa. 92 Overexpression of miR-107 can promote gastric cancer cell metastasis by suppressing miRNA-processing enzyme DICER1. Silencing of miR-107 inhibits invasion and metastasis of gastric cancer cells in vivo and in vitro. 93 Transfection of miR-181b in gastric cancer cells progressively facilitates their proliferation, invasion and migration. It may be another possible molecular target of gastric cancer treatment. 94 In several kinds of human gastric cancer cell lines, overexpression of miR-223 was a characteristic feature in metastatic gastric cancer cells. 95 Ectopic expression of miR-622 promotes invasion and metastasis of gastric cancer cells in vivo and in vitro by regulation of ING1 (inhibitor of growth 1) gene. 96 miRNAs associated with lymph node metastases in gastric cancer Lymphatic metastasis is the most common pathway of metastatic spread for malignant tumors and is known to have serious influence on the quality of life and prognosis of patients. Now it's been confirmed that there is a relation between miRNAs and invasion and metastasis of malignant tumors. [97] [98] [99] [100] Wu et al 101 have found that there was a significant difference in expression levels among 38 kinds of miRNAs in gastric cancer tissues and in their adjacent normal tissues. Further research found that 5 kinds of miRNAs were associated with tumor lymphatic metastasis and those tumors with high has-miR-195 level and low miR-212 level may be prone to lymphatic metastasis. The expression level of miR-21 in gastric cancer tissue associated with lymph node metastasis was significantly higher than those with no lymph node metastasis. 102 In human gastric cancer, miR-650 was also correlated with lymph node and distant metastasis. Ectopic expression of miR-650 promotes gastric tumorigenesis and cellular proliferation through regulation of the tumor suppressor ING4. 103 miRNAs and lymphangiogenesis It is now generally accepted that the formation of lymphatic vessels is the initial step of lymphatic metastasis as it provides many channels for the inevitable spread. 104 One study found that upregulated miR-1236 in human lymphatic endothelial cells significantly reduces expression of VEGFR-3 but not VEGFR-2 and that overexpression of miR-1236 may weaken migration and tube formation abilities of these cells by affecting generation of new lymphatic vessels. 105 Another comparative study of miRNA target genes shows that it is involved in lymph vessels generation in endothelial cells of normal lymphatics and in those of lymphatics derived from T-241/VEGF-C fibrosarcoma tumor metastasis model. Genotyping microarray methods preliminarily detected three kinds of lymphangiogenesis-related genes including endothelial cellselective adhesion molecule, TGFβ1/3 receptor Endoglin and angiogenesis related to Leptin receptor. 106 Relationship between miRNAs and lymphangiogenesis is becoming the hotspot in the research of tumor lymphatic metastasis. Further study on differential expression of miRNAs and their target genes may be helpful to find new diagnostic and therapeutic methods of cancer lymphatic metastasis.
miRNAs IN DIAGNOSIS OF GASTRIC CANCER
In the field of molecular markers for tumor diagnosis at the level of DNA and RNA, miRNAs showed unique superiority because of their stability and specificity. So, they have gained widespread attention. At present, finding miRNAs associated with early diagnosis and the prognosis of gastric cancer is becoming an actively growing area of research, but yet their validity as reliable tool in identification of benign and malignant tumors still remains to be further confirmed.
Some results suggested that expression of miRNAs in circulating blood of patients with gastric cancer significantly differed from that of healthy people and may even be consistent with miRNAs expression in gastric cancer tissue. Circulating miRNAs can be used as potential gastric cancer markers for diagnosis and monitoring of disease status. 107, 108 It was reported that miR-17-5p, miR-21 and miR-106a/b in the blood of the gastric cancer patients were significantly higher than the control group, while Let-7a was significantly reduced. 68 Circulating miR-21 level in gastric cancer patients are positively correlated with tumor lymph node metastasis, tumor-node metastasis stage, tumor size and histological type, so it may be used as a marker for gastric cancer detection. 109 In addition, miR-17 and miR-106a levels in peripheral blood of patients with gastric cancer were closely related to the number of tumor cells. Multivariate analysis confirmed that miR-143 and miR-195 could be associated with some clinicopathologic parameters including depth of invasion and lymph node metastasis. 110 It was found that expressions of miR-17 and miR-106a have obvious relevance to the number of gastric cancer cells as indicators and to the detection of peripheral circulating tumor cells as molecular tools. 111 miR-195-5p is a newly discovered tumor suppressor which may have an impact on gastric tumorigenesis. In a study on 740 kinds of miRNAs from the serum, the researchers found that only miR-195-5p expression level in serum of gastric cancer patients was significantly lower than control group. 112 Both miR-221 and miR-376c in sera of gastric cancer patients showed obviously positive correlation with low differentiation of their cancer cells, while miR-744 was reated to high proliferation rate of these cells. All these three miRNAs may serve as early biomarkers for noninvasive diagnosis of gastric carcinoma. 113 In 37 cases of tumor tissues and pericarcinoma tissues from gastric cancer patients, miR-21 expression level measured using quantitative PCR uncovered that miR-21 was overexpressed in 92% of these gastric cancer samples. So it may be used as an effective marker for gastric cancer diagnosis. 114 Overexpressed miR-21 binding to tumor suppressor gene PDCD4 by way of base pairing can inhibit PDCD4 protein expression. 115 miR-21 and PDCD4 are directly relevant to tumor size, invasion depth, lymph node metastasis and vascular invasion but not beneficial in determining the clinical prognosis of gastric cancer patients.
In gastric cancer tissues, concomitant changes of three miRNAs, increase of both miR-21 and miR-223 combined with decrease of miR-218, may be potential molecular markers for gastric cancer diagnosis. 116 Researchers have also found that downregulation of miR-31, which is associated with gastric tumorigenesis, could serve as a molecular marker for gastric cancer diagnosis. 117 In the intestinal-type of gastric cancer, three molecules involved in expression disorders including miR-32, miR-182 and miR-143, are generally associated with the pathological stage of tumor and may be potential diagnostic biomarkers for this type. 118 In another study, the miR-106a levels in 55 specimens of gastric cancer and 17 of non-gastric tumor tissues were determined. The result showed that miR-106a in gastric cancer tissue was 1.625 times Figure 1 . microRNAs and the invasion and metastasis of gastric cancer. Some specific microRNAs can regulate many important tumor-related genes involved in tumor progression to inhibit or promote invasion and metastasis of gastric cancer cells. Certain microRNAs were associated with tumor lymphatic metastasis. miRNA, microRNA.
higher than the control. What's more, level of miR-106a was closely related to tumor size, differentiation degree, lymph node affection and distant metastasis, so it can act as a useful molecular marker for gastric cancer diagnosis. 119 In comparison to the distal tissues, expression of miR-375 in gastric adenocarcinoma was significantly lowered. At the same time, downregulation of miR-375 in peripheral blood of these patients could also demonstrate its diagnostic role of gastric carcinoma. 120 In 60 cases of early gastric cancer, miR-421 in 73.33% of gastric cancer tissues was overexpressed. Furthermore, compared with carcinoembryonic antigen, serum miR-421 has significantly higher detection rate of gastric cancer. 121 Ueda et al. 122 have employed microarray technology to assess the expression spectrum of 353 kinds of miRNAs in gastric cancer samples compared with normal gastric tissues and to evaluate the relationship between the progression and prognosis of gastric cancer. It was found that 22 kinds of miRNAs were upregulated and 13 kinds of miRNAs were downregulated in 160 paired gastric cancer samples and diagnostic accuracy of gastric cancer was 83% by using the differential expressions of these miRNAs. These experimental results fully demonstrated that the utilization of miRNAs as new markers for gastric cancer diagnosis is promising and worthy of further exploration.
Beside peripheral blood and tumor tissues, differential expression of miRNAs in gastric juice from gastric cancer patients also began to draw the attention of the researchers. Levels of miR-21 and miR-106a in gastric juice have significant difference between patients with gastric cancer and patients with benign gastric diseases. 123 Research on miR-421 also showed similar findings. For the diagnosis of early gastric cancer, detection of miR-421 in gastric juice is gaining more improvement than single use of serum carcinoembryonic antigen. 124 
miRNAs AND THE PROGNOSIS OF GASTRIC CANCER
The prognosis of gastric cancer depends mainly on the probability of recurrence and metastasis. A large number of studies have shown that expression patterns of some miRNAs can be used for judging prognosis of gastric cancer. A case in a point is that the high expression of miR-20 and miR-150b, or the low expression of miR-451, is associated with poor prognosis in patients with gastric cancer. 125, 126 Expression of tumor suppressor miR-29 family members may also be used as new biomarkers for prognosis and therapeutic targets of gastric cancer patients. 47 miR-106b is another tumor promoter associated with poor prognosis of gastric cancer patients. 18 The study of 87 gastric cancer cases found that lower expression of miR-125a-5p often correlated with tumor size, invasion, liver metastasis and poor prognosis. Multivariate analysis showed that its downregulation is an independent prognostic factor for survival. So, miR-125a-5p could be a reliable prognostic marker. 127 The reduced miR-206 level in gastric cancer tissues is associated with higher degree of lymph node metastasis, distant metastasis and poor clinical stage. miR-206 has been proved to be an independent influence factor for the prognostic evaluation of patients with gastric cancer. 128 Studies of microRNA expression profiles suggested that variety of miRNAs were differentially expressed. Most of their expression patterns were associated with the prognosis of patients with gastric cancer.
Five kinds of miRNAs, namely miR-17-5p, miR-21, miR-106a, miR-106b and miR-7a, were screened out by miRNA chip from gastric cancer samples and could be steadily detected. 107 These miRNAs are demonstrated to be bound up with the highly malignant phenotype and to the poor prognosis of gastric cancer. 129, 130 In an analysis of miRNAs from 100 gastric cancer patients, the results showed that the expressions of seven miRNAs (miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-5p and miR-126) were significantly related to recurrence free periods and overall survival of patients. 131 A similar research has further confirmed that overexpression of miR-223 in primary gastric cancer was associated with less survival without metastasis. 95 A study involving 353 case of gastric cancer has found that miR-125b, miR-199a and miR-100 were associated with progression of gastric cancer. In addition, low expression of both Let-7g and miR-433 along with high expression of miR-214 were connected with the poor prognosis of patients, which reflected tumor infiltration depth, lymph node metastasis and tumor stage. 122 In tissues of advanced gastric cancer, the high expressions of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130, miR-155, miR-221 and miR-222 carried high risk for invasion through serous membrane, lymph node metastasis and distant metastasis and brought about poor long-term survival. 132 SUMMARY miRNAs have a vital role in the occurrence and development of gastric cancer. Accompanied with further research, this preliminary understanding uncovers an essential characteristics and biological function of miRNAs during the process of the formation and progression of gastric cancer. There is a growing need for distinguishing miRNAs between interacting with oncogenes or tumor suppressor genes and affecting invasion and metastasis. Some of these miRNAs may inhibit oncogenicity by combining with target genes, or suppress tumor growth, invasion and metastasis by raising the expression of tumor suppressor genes.
Expression levels of miRNAs may vary during different developmental stages of cancer tissues. The advancing technology of miRNA profiling microarray chips can speed up the study of the relationship between gastric cancer and miRNAs. In recent years, such researches have gained great progress and provided some new methods for clinical diagnosis and treatment, which may illuminate the risk of specific population and response to the treatment and thus assist in the prognosis assessment and cancer prevention.
In the meantime, miRNAs may become valuable diagnostic markers and therapeutic targets for numerous diseases including gastric carcinoma. In addition, it may be one of the promising anti-cancer therapies by modulating the expression of promptingcancer miRNAs using efficient gene knockout, antisense nucleotide and miRNA modification in the future.
